Fluzone®: Clinical Trials

6 trials of Fluzone®, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 5, Terminated 1

Follow Fluzone®: new trials by email Literature Review of Fluzone® trials Research Report on Fluzone®

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Quadrivalent Influenza Vaccine Among Children
Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative, Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative, Quadrivalent Influenza Vaccine, No Preservative - Influenza
Phase 3CompletedSanofi Pasteur, a Sanofi Company43632010-11-012015-07-14
Study of Quadrivalent Influenza Vaccine Among Adults
Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative, Investigational Trivalent Inactivated Influenza Vaccine, No Preservative, Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative - Influenza
Phase 3CompletedSanofi Pasteur, a Sanofi Company7392010-10-012013-10-23
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
GSK investigational vaccine GSK1557482A, Fluzone® - Influenza
Phase 3CompletedGlaxoSmithKline21162009-10-132018-09-21
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine - Influenza
Phase 3TerminatedSanofi91722009-09-012012-08-01
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Influenza Virus Vaccine USP Trivalent Types A and B - Orthomyxoviridae Infection, Influenza
Phase 3CompletedSanofi Pasteur, a Sanofi Company42922008-10-012016-04-14
Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults
Fluviral™, Fluzone® - Influenza
Phase 3CompletedGlaxoSmithKline10002005-01-012017-06-08

Conditions studied

Influenza, Human (6)  ·  Orthomyxoviridae Infections (1)  ·  Respiratory Tract Infections (1)

Sponsors

Sanofi Pasteur, a Sanofi Company (3)  ·  GlaxoSmithKline (2)  ·  Sanofi (1)

Countries

United States (5)  ·  Puerto Rico (2)

Results publications

PMID 22333695, PMID 23499604, PMID 24445833, PMID 29465480